Claims
- 1. A pharmaceutical composition in solid unit dosage form comprising (a) a therapeutically effective amount of a piperidinoalkanol compound, or a pharmaceutically acceptable salt thereof, (b) pharmaceutically acceptable nonionic surfactant in an amount of from about 0.1% to about 6% by weight of the composition, and (c) pharmaceutically acceptable carbonate salt in an amount of from about 2% to about 50% by weight of the composition.
- 2. A pharmaceutical composition according to claim 1 wherein the carbonate salt is calcium carbonate.
- 3. A pharmaceutical composition according to claim 2 wherein the piperidinoalkanol is .alpha.-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol.
- 4. A composition according to claim 3 wherein the .alpha.-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol is present in the amount of about 60 mg.
- 5. A composition according to claim 3 wherein the .alpha.-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol is present in the amount of about 120 mg.
- 6. A composition according to claim 4 or 5 wherein the nonionic surfactant is present in an amount of from about 2% to about 4% by weight of the composition.
- 7. A composition according to claim 4 or 5 wherein the nonionic surfactant is present in an amount of about 3% by weight of the composition.
- 8. A composition according to claim 4 wherein the nonionic surfactant is polysorbate 80.
- 9. A composition according to claim 5 wherein the nonionic surfactant is polysorbate 80.
- 10. A composition according to claim 4 or 5 wherein calcium carbonate is present in an amount of from about 2% to about 25% by weight of the composition.
- 11. A composition according to claim 4 or 5 wherein the calcium carbonate is present in an amount of from about 12% to about 18% by weight of the composition.
- 12. A composition according to claim 4 or 5 wherein the calcium carbonate is present in an amount of about 15% by weight of the composition.
- 13. A composition according to claim 8 wherein polysorbate 80 and calcium carbonate are present in amounts of about 3% and 15%, respectively, by weight of the composition, and further comprises, microcrystalline cellulose, pregelatinized corn starch, sodium starch glycolate and magnesium stearate in amounts of about 35%, 30%, 5%, and 0.5%, respectively, by weight of the composition.
- 14. A composition according to claim 9 wherein polysorbate 80 and calcium carbonate are present in amounts of about 3% and 15%, respectively, by weight of the composition, and further comprises, microcrystalline cellulose, pregelatinized corn starch, sodium starch glycolate and magnesium stearate in amounts of about 32%, 30%, 3%, and 0.5%, respectively, by weight of the composition.
- 15. A pharmaceutical composition in solid unit dosage form comprising (a) a therapeutically effective amount of a piperidinoalkanol compound, or a pharmaceutically acceptable salt thereof, (b) pharmaceutically acceptable cationic surfactant in an amount of from about 0.1% to about 6% by weight of the composition, and (c) pharmaceutically acceptable carbonate salt in an amount of from 2% to about 50% by weight of the composition.
- 16. A composition according to claim 15 wherein the carbonate salt is calcium carbonate.
- 17. A composition according to claim 16 wherein the piperidinoalkanol compound is piperidinoalkanol is .alpha.-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1-piperidinebutanol.
- 18. A composition according to claim 17 wherein the piperidinoalkanol is present in an amount of from about 10 mg to about 120 mg.
- 19. A composition according to claim 18 wherein the cationic surfactant is cetylpyridium chloride.
- 20. A composition according to claim 19 wherein cetylpyridium chloride and calcium carbonate are present in amounts of about 3% and 15%, respectively, by weight of the composition, and further comprises, microcrystalline cellulose, pregelatinized corn starch, sodium starch glycolate and magnesium stearate in amounts of about 35%, 30%, 5%, and 0.5%, respectively, by weight of the composition.
Parent Case Info
This is a continuation-in-part of application Ser. No. 152,689, filed Feb. 5, 1988, now abandoned, which is a continuation-in-part of application Ser. No. 117,166, filed Nov. 4, 1987, now abandoned, which is a continuation-in-part of application Ser. No. 105,928, filed Oct. 7, 1987, now abandoned.
US Referenced Citations (4)
Foreign Referenced Citations (1)
Number |
Date |
Country |
0264259 |
Apr 1988 |
EPX |
Non-Patent Literature Citations (1)
Entry |
Chemical Abstracts, vol. 86, No. 26, Jun. 27, 1977, abstract 86:195167R. |
Continuation in Parts (3)
|
Number |
Date |
Country |
Parent |
152689 |
Feb 1988 |
|
Parent |
117166 |
Nov 1987 |
|
Parent |
105928 |
Oct 1987 |
|